GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (NAS:TLRY) » Definitions » EV-to-EBIT

Tilray Brands (Tilray Brands) EV-to-EBIT

: -6.51 (As of Today)
View and export this data going back to 2015. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tilray Brands's Enterprise Value is $1,645.1 Mil. Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-252.7 Mil. Therefore, Tilray Brands's EV-to-EBIT for today is -6.51.

The historical rank and industry rank for Tilray Brands's EV-to-EBIT or its related term are showing as below:

TLRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -175.26   Med: -5.36   Max: 922.96
Current: -6.51

During the past 12 years, the highest EV-to-EBIT of Tilray Brands was 922.96. The lowest was -175.26. And the median was -5.36.

TLRY's EV-to-EBIT is ranked worse than
100% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.12 vs TLRY: -6.51

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tilray Brands's Enterprise Value for the quarter that ended in Feb. 2024 was $1,579.0 Mil. Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 was $-252.7 Mil. Tilray Brands's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 was -16.00%.


Tilray Brands EV-to-EBIT Historical Data

The historical data trend for Tilray Brands's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -50.04 -14.13 -25.15 -6.59 -0.89

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -0.89 -1.63 -1.19 -6.25

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tilray Brands's EV-to-EBIT falls into.



Tilray Brands EV-to-EBIT Calculation

Tilray Brands's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1645.141/-252.674
=-6.51

Tilray Brands's current Enterprise Value is $1,645.1 Mil.
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-252.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands  (NAS:TLRY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tilray Brands's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Feb. 2024 ) =EBIT / Enterprise Value (Q: Feb. 2024 )
=-252.674/1579.01144
=-16.00 %

Tilray Brands's Enterprise Value for the quarter that ended in Feb. 2024 was $1,579.0 Mil.
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-252.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tilray Brands EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tilray Brands's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (Tilray Brands) Business Description

Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.
Executives
Denise M Faltischek officer: Chief Strategy Officer C/O THE HAIN CELESTIAL GROUP, INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Mitchell Gendel officer: Global General Counsel EMERALD HOLDING, INC., 100 BROADWAY, 14TH FLOOR, NEW YORK NY 10005
Irwin D Simon director, officer: President & CEO C/O THE HAIN CELESTIAL GROUP INC., 1111 MARCUS AVENUE, LAKE SUCCESS NY 11042
Carl A Merton officer: Chief Financial Officer C/O TILRAY, INC., 745 FIFTH AVENUE, SUITE 1602, NEW YORK NY 10151
Brendan Kennedy director 1920 EASTLAKE AVENUE E., SEATTLE WA 98105
James R. Meiers officer: Head of Canada C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David G. Hopkinson director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Thomas P. Looney director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Johann Michael Herhalt director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
Jodi L. Butts director C/O TILRAY, INC., 655 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10065
David F Clanachan director TIM HORTONS INC., 874 SINCLAIR ROAD, OAKVILLE A6 L6K 2Y1
Renah Persofsky director 55 PRINCE ARTHUR AVENUE, #604, TORONTO A6 M5R 1B3
Jon Edward Levin officer: Chief Operating Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Michael C. Kruteck officer: Chief Financial Officer 2701 EASTLAKE AVE E, 3RD FLOOR, SEATTLE WA 98102
Rebekah Dopp director 444 LENOX AVENUE, SOUTH ORANGE NJ 07079